The European Medicines Agency Review of Abiraterone for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Adult Men After Docetaxel Chemotherapy and in Chemotherapy-Naïve Disease: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

On September 5, 2011, abiraterone was approved in the European Union in combination with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (CRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen. On December 18...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Gravanis, Iordanis, Lopez, Arantxa Sancho, Hemmings, Robert James, Jiménez, Jorge Camarero, Garcia-Carbonero, Rocio, Gallego, Isabel García, Giménez, Elena Valencia, O'Connor, Daniel, Giuliani, Rosa, Salmonson, Tomas, Pignatti, Francesco
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2013
Assuntos:
Regulatory Issues: EMA
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3780635/
https://ncbi.nlm.nih.gov/pubmed/23966222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0092
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares